PCV18: COST EFFECTIVENESS OF ENOXAPARIN VS. UNFRACTIONATED HEPARIN FOR THE PROPHYLAXIS OF DVT AND SUBSEQUENT LONG-TERM COMPLICATIONS IN TOTAL HIP REPLACEMENT SURGERY IN THE UNITED KINGDOM  by Botteman, M et al.
Abstracts 495
also resulted in a positive short- and long-term health
economic benefit in acutely ill medical patients. The
health-economic benefit of enoxaparin was positively re-
lated with the length of the follow-up period and a higher
risk for recurrence of VTE and mortality in asymptom-
atic patients.
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The post-thrombotic syndrome (PTS) is a serious long-
term complication of deep-vein thrombosis (DVT) that
may only be avoided by preventing the initial DVT. No
pharmacoeconomic assessment of low molecular weight
heparin (LMWH) has included the impact of reducing
these long-term complications in the UK.
OBJECTIVES: To determine the cost effectiveness of
LMWH (enoxaparin, 7 days, 40 mg daily) versus unfrac-
tionated heparin (UFH, 7 days, 15,000 units daily) for
the universal prophylaxis of DVT and PTS in patients un-
dergoing total hip replacement surgery (THRS).
METHODS: A probabilistic health-state transition model
using a Monte-Carlo (MC) simulation was developed to
project the long-term cost-effectiveness of the two strate-
gies in a cohort of 10,000 patients. The risk of develop-
ing a DVT in the short term (i.e., two weeks) was esti-
mated using epidemiological and clinical trial data. Patients
who survived a DVT in the short term were exposed to
the long-term risk of PTS and recurrent VTE whereas
other surviving patients were only exposed to the long-
term risk of idiopathic PTS and VTE. Economic literature
and expert opinion served as input for the model’s re-
source use and costs for DVT prophylaxis, clinical diag-
nosis and treatment of DVT, PE, and PTS. Five thousand
MC simulations were run on the model.
RESULTS: In the baseline, point-estimate analysis, LMWH
use prevented 240 DVTs and 13 deaths in the short term
compared to UFH, and resulted in net savings of £10 per
patient. In the long term, LMWH saved an additional
£36 in DVT complication costs. LMWH was the domi-
nant strategy in 70% of cases and was cost-effective in
72% overall.
CONCLUSION: This is the first economic analysis com-
paring LMWH and UFH that includes the long-term
complications of DVT. Our model indicates that the in-
clusion of these long-term complications supports the
widespread use of LMWH in patients undergoing THRS.
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OBJECTIVE: To estimate the cost-effectiveness of carvedilol
relative to bisoprolol as adjunctive beta blocker (BB) ther-
apy in patients with chronic heart failure.
METHODS: Comparison of survival benefits was per-
formed using the CIBIS-II placebo group as a representa-
tive cohort not treated with a BB. Using parametric sur-
vival analysis, five-year survival estimates were calculated
for bisoprolol and carvedilol based on published data for
the major mortality studies of the two BBs with similar
placebo mortality risks (CIBIS-II (hazard ratio 0.66) and
US Carvedilol Trial Program (hazard ratio 0.35)). Lim-
ited and extended benefit scenarios were estimated under
varying assumptions about the sustainability of BB treat-
ment effect. Under the limited benefits scenario the treat-
ment effect was conservatively assumed to last only until
the end of the reported trial periods. The extended bene-
fits scenario was assumed to persist up to five years. Tak-
ing the perspective of the UK NHS we estimated differ-
ences in treatment costs (medication, outpatient/GP visits,
hospitalization), and absolute mortality benefits to form
an incremental cost-effectiveness ratio.
RESULTS: The estimated benefit per patient at five years
under the extended benefits scenario was 145 days (0.398
yr.) for bisoprolol and 301 days (0.823 yr.) for carvedilol.
The corresponding figures for the limited benefits scenario
are 93 days (0.254 yr.) for bisoprolol and 119 days (0.325
yr.) for carvedilol. Over five years the estimated incremen-
tal cost-effectiveness ratio of carvedilol compared to biso-
prolol is £5,900 per LYG under limited and £1,800 per
LYG under extended benefit scenarios respectively.
CONCLUSIONS: Carvedilol represents a cost-effective
adjunctive treatment compared to bisoprolol in patients
with chronic heart failure. Statistical extrapolation indi-
cates that the relatively greater mortality benefits associ-
ated with carvedilol relative to bisoprolol are accrued at a
cost, which compares favourably with that of many other
common cardiovascular treatments such as statins and
ACE inhibitors.
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OBJECTIVE: The goal of this study is to evaluate and
determine the cost-effectiveness (CE) of a college of phar-
macy’s tobacco outreach program targeting thirteen- to
